Contrasting Molina Healthcare (NYSE:MOH) and China Cord Blood Corporation (CO)

China Cord Blood Corporation (NYSE: CO) and Molina Healthcare (NYSE:MOH) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, profitability and valuation.

Analyst Ratings

This is a breakdown of current ratings and price targets for China Cord Blood Corporation and Molina Healthcare, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
China Cord Blood Corporation 0 0 0 0 N/A
Molina Healthcare 3 5 4 0 2.08

Molina Healthcare has a consensus target price of $61.92, suggesting a potential upside of 3.83%. Given Molina Healthcare’s higher possible upside, analysts plainly believe Molina Healthcare is more favorable than China Cord Blood Corporation.

Earnings and Valuation

This table compares China Cord Blood Corporation and Molina Healthcare’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
China Cord Blood Corporation $113.18 million 13.70 $46.96 million $0.23 55.91
Molina Healthcare $18.51 billion 0.18 $106.00 million ($3.61) -16.52

Molina Healthcare has higher revenue and earnings than China Cord Blood Corporation. Molina Healthcare is trading at a lower price-to-earnings ratio than China Cord Blood Corporation, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

18.6% of China Cord Blood Corporation shares are held by institutional investors. Comparatively, 93.2% of Molina Healthcare shares are held by institutional investors. 6.2% of Molina Healthcare shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares China Cord Blood Corporation and Molina Healthcare’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
China Cord Blood Corporation 16.46% 7.05% 2.52%
Molina Healthcare -1.07% 16.10% 3.35%

Risk & Volatility

China Cord Blood Corporation has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Comparatively, Molina Healthcare has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500.

Summary

Molina Healthcare beats China Cord Blood Corporation on 8 of the 13 factors compared between the two stocks.

About China Cord Blood Corporation

China Cord Blood Corporation is a provider of cord blood banking services in China. The Company and its subsidiaries are principally engaged in the provision of umbilical cord blood storage and ancillary services in the People’s Republic of China. It provides cord blood testing, processing and storage services under the direction of subscribers for a cord blood processing fee and a storage fee. It also tests, processes and stores donated cord blood, and provides matching services to the public for a fee. The Company provides cord blood processing and storage services for expectant parents interested in capturing the opportunities made available by evolving medical treatments and technologies, such as cord blood transplants. It also preserves cord blood units donated by the public; provides matching services on such donated units, and delivers matching units to patients in need of transplants. As of March 31, 2016, the Company had three operating cord blood banks.

About Molina Healthcare

Molina Healthcare, Inc. offers Medicaid-related solutions for low-income families and individuals, and assists government agencies in their administration of the Medicaid program. The Company operates through three segments: Health Plans, Molina Medicaid Solutions and Other, which includes its Pathways Health and Community Support LLC (Pathways) business. It arranges healthcare services for persons served by Medicaid, Medicare, the Children’s Health Insurance Program (CHIP) and the Marketplace, and products to assist government agencies in their administration of the Medicaid program. As of December 31, 2016, the Company’s Health Plans segment consisted of health plans in 12 states and the Commonwealth of Puerto Rico, and its direct delivery business. The Molina Medicaid Solutions segment provides support to state government agencies in the administration of their Medicaid programs, including business processing, information technology development, and administrative services.

Receive News & Ratings for China Cord Blood Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Cord Blood Corporation and related companies with our FREE daily email newsletter.

 

Latest News



Leave a Reply

 
© 2006-2017 Rincon Hill News.